BPC-157
Body Protection Compound-157
Molecular Details
Overview
BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a naturally occurring protein found in human gastric juice. First characterized in the early 1990s, it has since become one of the most extensively studied peptides in preclinical research. Unlike typical peptides, BPC-157 demonstrates notable stability in gastric environments, resisting degradation by pepsin and other gastric proteases.
Published Research
Tendon Fibroblast Enhancement
In vitro / Animal · 2018Researchers observed that BPC-157 enhances growth hormone receptor expression in tendon fibroblasts and promotes fibroblast migration and tendon outgrowth in a dose-dependent manner.
Alkali-Burn Wound Healing Model
In vivo (rat) · 2015Topical BPC-157 application accelerated wound closure in rat models of alkali skin burns, with improvements in granulation tissue formation, re-epithelialization, and dermal remodeling. Researchers identified activation of the ERK1/2 signaling pathway.
Mechanism of Action — Signaling Pathways
Multiple models · 2010–2024Researchers identified that BPC-157 activates multiple overlapping pathways, notably VEGFR2 and nitric oxide synthesis via the Akt-eNOS axis, alongside ERK1/2 signaling, promoting angiogenesis and exerting anti-inflammatory effects.
Cardiovascular — Collateral Vessel Activation
In vivo (rat) · 2018BPC-157 was observed to counteract major vessel occlusion syndromes by rapidly activating collateral blood vessel pathways in rat models of superior mesenteric artery and vein occlusion.
Neurological Protection — Ischemia Model
In vivo (rat) · 2021Studies demonstrated that BPC-157 administration counteracted bilateral common carotid artery clamping-induced stroke effects and resolved sustained neuronal damage in rat hippocampal tissues through gene expression modulation.
Storage & Handling
Store lyophilized powder at –20°C or below. Reconstituted solutions should be refrigerated at 2–8°C and used within 4–6 weeks. Minimize freeze-thaw cycles. Consider adding carrier protein (0.1% HSA or BSA) for extended storage of reconstituted solutions.
For research purposes only. Not intended for human consumption. This profile summarizes published preclinical literature and does not constitute medical, clinical, or dosage guidance.